Trinity Capital Invests $45 Million in Rapid Micro Biosystems

September 22, 2025
Trinity Capital has committed $45 million in growth capital to Rapid Micro Biosystems to support its automation solutions in healthcare manufacturing.

Trinity Capital Inc. has committed $45 million in growth capital to Rapid Micro Biosystems, announced in a press release. Rapid Micro Biosystems specializes in automating microbial quality control processes, which are crucial for the efficient manufacturing and safe release of healthcare products.

The investment will aid in scaling Rapid Micro's operations, including the global expansion of its Growth Direct platform. This platform automates microbial quality control testing, providing faster and more accurate results, thereby enhancing operational efficiency and data integrity. The funding will also support efforts to reduce product costs and improve manufacturing efficiencies.

Robert Spignesi, President and CEO of Rapid Micro Biosystems, expressed satisfaction with the partnership, highlighting the shared vision of automating manual testing methods in biopharma manufacturing. This financial boost is expected to strengthen Rapid Micro's market position and support its long-term growth objectives.

We hope you enjoyed this article.

Consider subscribing to one of our newsletters like AI Funding Brief, Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

AI Funding News Healthcare & Life Sciences AI AI Brief AI Brief (X)

More from: Funding

09/22
V2X Completes Acquisition of QinetiQ US Intelligence Business
09/22
xAI Aims for $200 Billion Valuation with New Funding Round
09/22
Nvidia Acquires Enfabrica CEO and Technology for $900 Million
09/22
Nvidia Considers $500M Investment in Wayve for Self-Driving Tech
09/21
Arkade AI Acquires Loop Marketers to Enhance AI-Driven Lead Generation

More from: Life Sciences

09/22
Lunit and Agilent Collaborate on AI-Powered Diagnostic Solutions
09/22
DwellSafe Launches AI Home Safety Platform for Aging Adults
09/22
Amorepacific Showcases AI Innovations in Skincare at IFSCC Congress
09/22
TransMedics and Mercedes-Benz Launch Organ Transport Network in Italy
09/21
States of Mind Launches European Platform for Advanced Mental Health

Subscribe to Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

AI Token Webinar

Industry analysis

2025 Global Business Services Agenda: Gen AI Takes Center Stage

The Hackett Group

This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.

Read more

You May Also Like